CA2387559A1 - N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent - Google Patents

N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent Download PDF

Info

Publication number
CA2387559A1
CA2387559A1 CA002387559A CA2387559A CA2387559A1 CA 2387559 A1 CA2387559 A1 CA 2387559A1 CA 002387559 A CA002387559 A CA 002387559A CA 2387559 A CA2387559 A CA 2387559A CA 2387559 A1 CA2387559 A1 CA 2387559A1
Authority
CA
Canada
Prior art keywords
cell
protein
pro
inflammatory
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002387559A
Other languages
English (en)
French (fr)
Inventor
James A. Clagett
Craig Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mowycal Lending LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2387559A1 publication Critical patent/CA2387559A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA002387559A 1999-10-15 2000-10-12 N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent Abandoned CA2387559A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15967799P 1999-10-15 1999-10-15
US60/159,677 1999-10-15
PCT/US2000/028183 WO2001029069A1 (en) 1999-10-15 2000-10-12 N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent

Publications (1)

Publication Number Publication Date
CA2387559A1 true CA2387559A1 (en) 2001-04-26

Family

ID=22573520

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387559A Abandoned CA2387559A1 (en) 1999-10-15 2000-10-12 N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent

Country Status (16)

Country Link
EP (1) EP1222199A4 (de)
JP (1) JP2004507441A (de)
KR (1) KR20020057972A (de)
CN (1) CN100497374C (de)
AU (1) AU8014200A (de)
BR (1) BR0014742A (de)
CA (1) CA2387559A1 (de)
CZ (1) CZ20021342A3 (de)
EA (1) EA200200451A1 (de)
HU (1) HUP0203688A2 (de)
IL (1) IL149125A0 (de)
MX (1) MXPA02003782A (de)
NO (1) NO20021732L (de)
PL (1) PL356096A1 (de)
WO (1) WO2001029069A1 (de)
ZA (1) ZA200202937B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138692A1 (de) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (de) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Genregulation durch Oligopeptide
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
WO2004100978A1 (en) * 2003-05-13 2004-11-25 Medvet Science Pty. Ltd. A method of modulating cellular transmigration and agents for use therein
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (de) 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden
US20110082091A1 (en) * 2009-09-28 2011-04-07 Theramab Gmbh Method for Preclinical Testing of Immunomodulatory Drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840851D1 (de) * 1997-11-13 2009-07-09 Mowycal Lending Llc Kleine peptide und methoden zur behandlung von asthma und entzündungen

Also Published As

Publication number Publication date
EA200200451A1 (ru) 2002-10-31
PL356096A1 (en) 2004-06-14
NO20021732L (no) 2002-06-12
JP2004507441A (ja) 2004-03-11
NO20021732D0 (no) 2002-04-12
BR0014742A (pt) 2002-08-27
MXPA02003782A (es) 2002-12-13
WO2001029069A1 (en) 2001-04-26
ZA200202937B (en) 2003-09-23
IL149125A0 (en) 2002-11-10
CN100497374C (zh) 2009-06-10
EP1222199A1 (de) 2002-07-17
EP1222199A4 (de) 2003-03-12
CN1633447A (zh) 2005-06-29
KR20020057972A (ko) 2002-07-12
AU8014200A (en) 2001-04-30
CZ20021342A3 (cs) 2003-01-15
HUP0203688A2 (hu) 2003-02-28

Similar Documents

Publication Publication Date Title
US9066905B2 (en) Synthetic peptides and methods of use for autoimmune disease therapies
Stevenson et al. Myristyl acylation of the tumor necrosis factor alpha precursor on specific lysine residues.
Offermanns et al. Gq and G11 are concurrently activated by bombesin and vasopressin in Swiss 3T3 cells
CA2387559A1 (en) N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent
KR100457350B1 (ko) ＩｇＥ-의존적 히스타민 방출인자(ＨＲＦ)의 수용체,ＨＲＦ 결합 펩타이드 및 그들을 코딩하는 핵산, 및그들의 용도
Derian et al. Selective inhibition of N-formylpeptide-induced neutrophil activation by carbamate-modified peptide analogues
Goetzl et al. Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis.
Balboni et al. Opioid diketopiperazines: synthesis and activity of a prototypic class of opioid antagonists
Kozlov et al. A sea anemone polypeptide toxin inhibiting the ASIC3 acid-sensitive channel
JP2002528389A (ja) Ｉｌ−２及びその類似体から誘導される抗炎症性ペプチド
Navolotskaya et al. Effect of synthetic β-endorphin-like peptide immunorphin on human T lymphocytes
Szatmári et al. Influence of degradation on binding properties and biological activity of endomorphin 1
US7132505B1 (en) Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
EP1280895A2 (de) Protonen-abhängiges na+kanal hemmendes polypeptid
Radel et al. Structural and functional characterization of the human formyl peptide receptor ligand-binding region
CA2152141A1 (en) Monocyte chemoattractant protein (mcp)-1 antagonists
Landis et al. Synthesis of highly. mu. and. delta. opioid receptor-selective peptides containing a photoaffinity group
Biondi et al. Opioid peptides: synthesis and biological activity of new endomorphin analogues
AU2001264892B2 (en) Modulaton of alpha-6 integrin-mediated responses
Rita et al. Effects of synthetic peptides on the inflammatory response and their therapeutic potential
AU2001264892A1 (en) Modulaton of alpha-6 integrin-mediated responses
US4749685A (en) Immunosuppressive peptides
Kohidai et al. Characterization of chemotactic ability of peptides containing N‐formyl‐methionyl residues in Tetrahymena fMLP as a targeting ligand
Takahashi et al. Characterization of cytosolic pertussis toxin-sensitive GTP-binding protein in mastocytoma P-815 cells
RU2036930C1 (ru) Пептиды и композиция на их основе, способная регулировать иммунную функцию млекопитающих

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued